Cannabinoids and psychosis
- PMID: 17349865
- DOI: 10.1016/S0074-7742(06)78010-2
Cannabinoids and psychosis
Abstract
Recent epidemiological studies and advances in understanding of brain cannabinoid function have renewed interest in the long-recognized association between cannabinoids and psychosis. This chapter presents evidence supporting and refuting the association between cannabinoids and psychosis. Cannabinoids can induce acute transient psychotic symptoms or an acute psychosis in some individuals. What makes some individuals vulnerable to cannabinoid-related psychosis is unclear. Also clear is that cannabinoids can also exacerbate psychosis in individuals with an established psychotic disorder, and these exacerbations may last beyond the period of intoxication. Less clear is whether cannabis causes a persistent de novo psychosis. The available evidence meets many but not all the criteria for causality, including dose-response, temporality, direction, specificity, and biological plausibility. On the other hand, the large majority of individuals exposed to cannabinoids do not experience psychosis or develop schizophrenia and the rates of schizophrenia have not increased commensurate with the increase in rates of cannabis use. Similar to smoking and lung cancer, it is more likely that cannabis exposure is a component cause that interacts with other factors, for example, genetic risk, to "cause" schizophrenia. Nevertheless, in the absence of known causes of schizophrenia, the role of component causes such as cannabis exposure (exogenous hypothesis) is important and warrants further study. There is also tantalizing evidence from postmortem, neurochemical, and genetic studies suggesting CB1 receptor dysfunction (endogenous hypothesis) in schizophrenia that warrants further investigation. Further work is necessary to identify those factors that place individuals at higher risk for cannabinoid-related psychosis, to identify the biological mechanisms underlying the risks and to further study whether CB1 receptor dysfunction contributes to the pathophysiology of psychotic disorders.
Similar articles
-
Cannabinoids and psychosis.Int Rev Psychiatry. 2009 Apr;21(2):152-62. doi: 10.1080/09540260902782802. Int Rev Psychiatry. 2009. PMID: 19367509 Review.
-
Cannabis, cannabinoids and schizophrenia: integration of the evidence.Aust N Z J Psychiatry. 2008 May;42(5):357-68. doi: 10.1080/00048670801961156. Aust N Z J Psychiatry. 2008. PMID: 18473254 Review.
-
Cannabis use and psychotic disorders: an update.Drug Alcohol Rev. 2004 Dec;23(4):433-43. doi: 10.1080/09595230412331324554. Drug Alcohol Rev. 2004. PMID: 15763748 Review.
-
Cannabis and psychiatric disorders: it is not only addiction.Addict Biol. 2008 Jun;13(2):264-75. doi: 10.1111/j.1369-1600.2008.00106.x. Addict Biol. 2008. PMID: 18482435 Review.
-
Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia.Arch Gen Psychiatry. 2008 Nov;65(11):1269-74. doi: 10.1001/archpsyc.65.11.1269. Arch Gen Psychiatry. 2008. PMID: 18981338
Cited by
-
Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial.Trials. 2023 Nov 30;24(1):775. doi: 10.1186/s13063-023-07789-w. Trials. 2023. PMID: 38037108 Free PMC article.
-
Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation.Front Behav Neurosci. 2023 Mar 16;17:1137957. doi: 10.3389/fnbeh.2023.1137957. eCollection 2023. Front Behav Neurosci. 2023. PMID: 37009000 Free PMC article. Review.
-
Delta-8-THC association with psychosis: A case report with literature review.Front Psychiatry. 2023 Feb 20;14:1103123. doi: 10.3389/fpsyt.2023.1103123. eCollection 2023. Front Psychiatry. 2023. PMID: 36890985 Free PMC article.
-
Levetiracetam-Induced Psychosis in the Setting of Intracranial Cavernomas.Case Rep Psychiatry. 2022 Mar 21;2022:9114118. doi: 10.1155/2022/9114118. eCollection 2022. Case Rep Psychiatry. 2022. PMID: 35356150 Free PMC article.
-
Marijuana Use and Driving Under the Influence among Young Adults: A Socioecological Perspective on Risk Factors.Subst Use Misuse. 2018 Feb 23;53(3):370-380. doi: 10.1080/10826084.2017.1327979. Epub 2017 Aug 4. Subst Use Misuse. 2018. PMID: 28777692 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical